Phialogics AG
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Phialogics AG - overview
Established
2021
Location
-, -, Switzerland
Primary Industry
Biotechnology
About
Based in Switzerland, and founded in 2021, Phialogics AG operates as a biotechnology company that develops therapies for autoimmune diseases. The company was founded by its CEO and CSO, Andreas Ernst, CBO Pascal Oromi, Michael J. Parnham, Andreas Weigert, and Andreas von Knethen. In April 2023, Phialogics AG raised EUR 0.
06 million in pre-seed funding led by High-Tech Gründerfonds. Phialogics develops novel therapeutics and immune-modulating therapeutics for patients with autoimmune illnesses. The company offers an immune tolerance platform, which is a biotech platform that develops cell-type-specific immune checkpoint activators to protect patients’ tissue from autoimmune attacks. The firm's technology involves identifying checkpoints on immune cells and designing small molecules that can activate those checkpoints selectively.
Current Investors
High-Tech Gruenderfonds
Primary Industry
Biotechnology
Sub Industries
Molecular Science, Genetics & Gene Therapy, Biopharmaceuticals, Pharmaceutical Research & Development
Website
www.phialogics.com
Company Stage
Early Stage
Total Amount Raised
Subscriber access only
Phialogics AG - employee data
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.